AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 202 min read$COR

COR Maintained by Argus Research -- Price Target Raised to $380

Argus Research maintained a 'Buy' rating on Cencora (COR) and raised its price target to $380 from $340. The company's GF Value™ suggests it is 11.3% overvalued, with a GF Score™ of 70/100. Insider activity shows significant selling, totaling $4.69 million over the last three months. Cencora operates in pharmaceutical distribution with a market cap of $64.88 billion.

Original reporting
gurufocus.com
Published Oct 20, 2026, 1:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$COR
Neutral
high confidence
Mentioned
$COR
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$CORNeutralMed
01

Why it matters

The analyst upgrade provides fresh valuation perspective; insider sales introduce a risk factor.

02

Market read

New analyst target raise could attract buying interest, while insider sell‑off may cause caution.

03

What to watch

The low momentum rating (2/10) indicates the stock may struggle to sustain price gains even with a higher target.

Relevance 7/10Novelty 7/10Timing: today

Background

Cencora, formerly AmerisourceBergen, is a leading pharmaceutical distributor with a $64.9B market cap.

Company-level read

Ticker impact

$CORNeutralHigh confidence
Context

Argus Research maintained a Buy rating and raised the price target for Cencora (COR) to $380 from $340, providing fresh analyst coverage.

Expected impact

modest upward pressure as investors price in the higher target, offset by potential downside from insider sales

Evidence & confidence

Target increase is a new, material analyst action for a large-cap stock; insider sales introduce a counter‑balance risk.

Market effects

Sector

The raise may lift sentiment in the broader healthcare distribution sector.

Regional

U.S. market focus; limited regional spillover.

Global

Minimal global impact beyond Cencora's international operations.

Counterpoint

What could challenge this read

Insider selling of nearly $5M could signal concerns, suggesting a short‑term pullback despite the target hike.

Key entities

  • Analyst Firm
    Argus Research

    Maintained Buy rating and raised price target for COR.

  • Company
    Cencora Inc.

    Healthcare distribution company subject of the rating update.

Read at source← All news

StoryArgus raises Cencora price target to $380

Also covered by

1 outlet

Related articles

OCT 21
$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

SEC EDGAR 8-K2 min
OCT 21
$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

investing.com2 min
OCT 21
$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

tradingview.com1 min
OCT 21
HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.

stocktitan.net2 min
OCT 20
$CORMed

Cencora stock price target raised to $380 by Argus on growth outlook

Argus raised its price target on Cencora Inc. (NYSE:COR) to $380, citing sustainable earnings growth and an attractive valuation. The company reported Q3 2026 adjusted earnings of $4.48 per share on $84.8 billion revenue, exceeding expectations. Cencora increased its full-year profit outlook despite some Walgreens volume moving away. RBC Capital maintained a Sector Perform rating with a $330 price target, noting growth in specialty pharma but lacking high-margin businesses.

investing.com2 min
SEP 19
$CORHighAI 8/10

Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?

Cencora (COR) reported Q3 revenue of $84.8B (+5.1%) and adjusted EPS of $4.48 (+12.0%). The company raised its full-year adjusted EPS outlook to $17.75-$17.95 and repurchased $1B in stock. Adjusted operating income rose 17.0%, driven by gross profit growth and the OneOncology acquisition. However, operating expenses increased 26.8%, and financing costs rose due to new debt. Lower-margin GLP-1 drugs and lost customers impacted revenue growth.

yahoo.com2 min